Treatment of malignant mesothelioma with methotrexate and vinblastine, with or without platinum chemotherapy

Chest

Volumn 109, Issue 5, 1996, Pages 1239-1242

  Hunt, Karen J ^a   Longton, Gary ^a   Williams, Margaret A ^a   Livingston, Robert B ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

carboplatin; chemotherapy; cisplatin; mesothelioma; methotrexate; vinblastine

Indexed keywords

CARBOPLATIN; CISPLATIN; METHOTREXATE; VINBLASTINE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HEPATITIS; HUMAN; INOPERABLE CANCER; INTRAVENOUS DRUG ADMINISTRATION; MALE; MALIGNANT MESOTHELIOMA; PARESTHESIA; PNEUMONIA; PRIORITY JOURNAL; TINNITUS; VOMITING;

EID: 0029916864     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.109.5.1239     Document Type: Article

References (17)

1. Vogelzang NJ. Malignant mesothelioma: diagnostic and management strategies for 1992. Semin Oncol 1992; 19:64-71
2. Sridhar KS, Doria R, Raub WA, et al. New strategies are needed in diffuse malignant mesothelioma. Cancer 1992; 70:2960-79
3. Branscheid D, Krysa S, Bauer E, et al. Diagnostic and therapeutic strategy in malignant pleural mesothelioma. Eur J Cardiothorac Surg 1991; 5:466-72
4. Rusch VW. Diagnosis and treatment of pleural mesothelioma. Semin Surg Oncol 1990; 6:279-85
5. Achatzy R, Beba W, Ritschler R, et al. The diagnosis, therapy and prognosis of diffuse mesothelioma. Eur J Cardiothorac Surg 1989; 3:445-47
6. Ruffie P, Feld R, Minkin S, et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol 1989; 7:1157-68
7. Krarup-Hansen A, Hansen BH. Chemotherapy in malignant mesothelioma: a review. Cancer Chemother Pharmacol 1991; 28:319-30
8. Alberts AS, Falkson G, Goedhals L, et al. Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers. J Clin Oncol 1988; 6:527-35
9. Weiss A, Lackman R. Chemotherapy of desmoid tumors and fibromatosis [abstract]. Proc Am Soc Clin Oncol 1994; 13:401
10. Weiss AJ, Lackman RD. Low-dose chemotherapy of desmoid tumors. Cancer 1989; 64:1192-94
11. Zidar BL, Green S, Pierce III, et al. A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a South-west Oncology Group study. Invest New Drugs 1988; 6:223-26
12. Planting AS, Schellens JH, Goey SH, et al. Weekly high dose cisplatin in malignant pleural mesothelioma. Ann Oncol 1994; 5:373-74
13. Mintzer DM, Kelsen D, Frimmer D, et al. Phase II trial of high dose cisplatin in patients with malignant mesothelioma. Cancer Treat Rep 1985; 69:711-12
14. Kalbfleish JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley & Sons, 1980; 10-6
15. Antman K, Shemin R, Ryan L, et al. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades. 1965-1985. J Clin Oncol 1988; 6:147-53
16. Chahinian AP, Pajak TK, Holland JF, et al. Diffuse malignant mesothelioma: prospective evaluation of 69 patients. Ann Intern Med 1982; 96:746-55
17. Jett JR, Su JQ, Krook JE, et al. Measurable or assessable disease in lung cancer trials: does it matter? J Clin Oncol 1994: 12:2677-81